Novo – Anthropic Claude Science partnership became official on September 16, 2026, when Novo Nordisk A/S and Anthropic announced they will work together to accelerate the discovery and development of new medicines while strengthening AI-driven software engineering across Novo‘s operations. The companies said the collaboration will jointly address drug discovery obstacles already identified by Novo’s scientists and computational teams in Bagsværd, Denmark.
Under the arrangement, Novo will use Anthropic’s frontier AI models together with Claude Science, a scientific-reasoning platform, to support biological reasoning and agentic software engineering inside its research and development organization. Novo described the effort as an extension of its existing AI initiatives with other technology partners, rather than a standalone experiment.
As an initial step, Novo will test Claude Science on specific R&D workflows and prioritize scientific problems where the combined capabilities of the two companies are expected to deliver the greatest impact. Novo Nordisk said this phased approach will let its computational biology and chemistry teams evaluate where AI reasoning tools add the most measurable value before wider rollout.
The Novo – Anthropic Claude Science partnership also extends beyond laboratory science into how Novo builds internal technology. Novo said it will use Anthropic’s frontier models to strengthen AI-driven software development, which the company frames as a key enabler for scaling artificial intelligence use across its broader organization of more than 67,000 employees worldwide.
Novo Nordisk positioned the announcement within its longer-running effort to modernize research operations through digital tools, noting that scientific and computational teams had already flagged specific drug discovery bottlenecks the two companies now plan to target jointly. The company said it expects the work to unfold gradually, starting with narrowly scoped scientific problems rather than an organization-wide deployment on day one.
Novo – Anthropic Claude Science Deal: What the Companies Announced
According to the joint statement, the companies will jointly address key drug discovery challenges identified by Novo scientists, develop targeted solutions for specific scientific workflows, and help accelerate the path from early research to approved medicines. Novo Nordisk framed the initiative as another step toward becoming what it calls the world’s most AI-driven healthcare company.
Mike Doustdar, president and CEO of Novo Nordisk, said joining forces with Anthropic will “supercharge our R&D organisation.” He added that artificial intelligence can help increase R&D productivity and compress the path from research to a marketed product, while also opening entirely new scientific opportunities for understanding human biology and drug mechanics.
Novo Nordisk did not disclose the financial terms of the collaboration in its announcement. The company also did not specify a timeline for when Claude Science tools might move from pilot workflows into broader production use across its research organization, and no specific drug programs were named as initial test cases.
How the Novo – Anthropic Claude Science Collaboration Will Work in R&D
The Novo Nordisk Anthropic Claude Science collaboration is structured around two parallel tracks: scientific reasoning support for drug discovery and agentic software engineering for internal technology development. Novo said targeted solutions will be built for specific scientific challenges and workflows rather than deployed as a single, generic tool across the organization.
Anthropic co-founder and CEO Dario Amodei said the growing capability of artificial intelligence carries the potential to compress a century’s worth of biological and medical breakthroughs into a decade. He said giving researchers access to safe, capable, and trusted frontier models can shorten research timelines and help discover treatments that meaningfully improve human life.
Novo Nordisk said the Novo Nordisk Anthropic Claude Science partnership has been designed with what it describes as robust data governance and human oversight, intended to ensure AI tools are applied responsibly and in line with the company’s existing ethical and compliance standards. Neither company detailed the specific technical or contractual mechanisms underpinning that oversight.
The collaboration builds on Novo’s prior use of Anthropic’s technology. Novo previously built NovoScribe, an internal generative AI platform running on Claude models via Amazon Bedrock, which the company has used to draft clinical study reports. That existing relationship gives the Novo Nordisk Anthropic Claude Science partnership a working foundation rather than a cold start between the two organizations.
Executives Frame the Novo – Anthropic Claude Science Partnership as Strategic
Both companies positioned the announcement as a strategic commitment rather than a limited pilot. Novo Nordisk pointed to its broader ambition of becoming the world’s most AI-driven healthcare company, building on prior AI collaborations with other technology providers across its research and manufacturing operations.
Amodei’s comments emphasized Anthropic’s stated mission of making frontier AI systems available to researchers working on real-world scientific and medical problems. Novo, for its part, emphasized that AI tools are expected to aid reasoning and understanding of human biology and drug mechanics beyond simple productivity gains, though the company did not quantify expected efficiency improvements.
Neither Novo Nordisk nor Anthropic outlined specific performance benchmarks or success metrics the Novo Nordisk Anthropic Claude Science partnership will be measured against in its initial phase. Both companies instead described the collaboration in directional terms, tying it to longer-term goals around research productivity, scientific reasoning, and responsible AI governance rather than near-term financial or clinical targets.
Novo – Anthropic Claude Science Deal Fits a Broader AI-in-Pharma Race
The Novo Nordisk Anthropic Claude Science partnership arrives as major drugmakers race to apply artificial intelligence across research pipelines. Eli Lilly announced a joint AI drug-discovery lab with Nvidia in January 2026, committing up to one billion dollars over five years, while Moderna has partnered with OpenAI to deploy AI tools across its operations. Novo Nordisk itself previously worked with Nvidia and Denmark’s DCAI initiative on the Gefion sovereign AI supercomputer for early research and clinical development.
Industry observers note the timing coincides with intensifying competition in obesity and diabetes care, where Novo Nordisk’s pipeline includes CagriSema, a combination of semaglutide and the amylin-based compound cagrilintide currently in late-stage trials. Novo Nordisk did not link the Anthropic collaboration to any specific pipeline program in its announcement, and the company said it will present 44 abstracts at a European diabetes symposium later this month, separate from the AI announcement.
For now, the Novo Nordisk Anthropic Claude Science partnership remains in an evaluation phase, with Novo testing Claude Science across selected R&D workflows before any broader commitment. Both companies said further details on scope and outcomes were not immediately provided, and neither firm set a public date for reporting results from the initial pilot workflows.
Investors and industry watchers are likely to look for updates on the Novo Nordisk Anthropic Claude Science partnership alongside Novo’s future quarterly disclosures, given the company’s pattern of referencing AI initiatives in investor communications. Until then, the announcement stands as a stated intent to combine Novo’s drug development expertise with Anthropic’s frontier AI research, without additional financial or operational specifics disclosed publicly as of this writing.
